Sorafenib is a multi-kinase inhibitor targeting RAF, PDGFRB, VEGFR2, FLT3, and KIT, and induces apoptosis in AML cells via BIM and downregulation of MCL-1109,110. The gene discussed is FLT3; the disease is acute myeloid leukemia.